Danish Commercial Services Stock News

Genmab (CPSE:GMAB) has reported new clinical data for its antibody drug conjugate rinatabart sesutecan, known as Rina S, in advanced ovarian cancer. The therapy, in combination with bevacizumab, showed a tolerable safety profile with no new or unexpected safety signals in patients. The results were presented at a major oncology conference, adding fresh information on Genmab’s oncology pipeline. For investors tracking Genmab, the update on Rina S comes with the share price at DKK1,804.0 and...

Swiss Properties Invest A/S' ( CPH:SWISS ) stock wasn't much affected by its recent lackluster earnings numbers. We did...

Wondering whether Novo Nordisk at around DKK 262.20 is offering value or just noise in a volatile market? This article breaks down what the price tag might really be telling you. The stock has moved 10.1% over the past week and 5.2% over the past month, while the year-to-date return stands at a 20.6% decline and the 1-year return at a 34.9% decline, which may catch the eye of investors weighing potential opportunity against risk. Recent coverage has focused on how sentiment toward large...

Vestas Wind Systems (CPSE:VWS) is back in focus after securing a 70 MW order for the Strazhitsa wind project in Bulgaria, paired with a long term service deal and fresh governance updates. See our latest analysis for Vestas Wind Systems. The recent 70 MW Bulgarian order, dividend approval and board changes arrive as Vestas posts a 27.0% 1 month share price return and a very large 1 year total shareholder return. However, the 5 year total shareholder return of a 15.57% decline shows that...

Novo Nordisk recently announced a wide-ranging partnership with OpenAI to integrate advanced AI across drug discovery, manufacturing, supply chain and commercial operations, with pilot projects underway and full roll-out targeted by the end of 2026 under strict data governance and human oversight. This collaboration could reshape how Novo Nordisk develops and delivers treatments by using AI to interpret complex datasets, shorten research timelines and support more efficient global operations...

Alm. Brand (CPSE:ALMB) has drawn attention after extending its collaboration with Ondo InsurTech’s LeakBot. The insurer plans to offer the leak detection device to up to 160,000 homeowners across its Danish insurance brands. See our latest analysis for Alm. Brand. The expanded LeakBot rollout and recent AGM decisions come after a weaker short term patch, with a 90 day share price return of 16.44% decline and year to date share price return of 17.74% decline, set against a 1 year total...

TORM plc ( CPH:TRMD A ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...

As European markets experience a rally, with the STOXX Europe 600 Index climbing over 3% amid easing geopolitical tensions, investors are increasingly focused on identifying value opportunities within this buoyant environment. In such conditions, a good stock is often characterized by its potential to be undervalued relative to intrinsic estimates, offering a promising avenue for those seeking to capitalize on market optimism while maintaining an eye toward long-term fundamentals.

Readers hoping to buy Scandinavian Tobacco Group A/S ( CPH:STG ) for its dividend will need to make their move shortly...

CK Hutchison has taken A.P. Møller - Mærsk to arbitration in London over Panama port assets after APM Terminals was appointed interim operator, adding legal complexity to an already politically sensitive dispute involving Panama, the US and China. At the same time, Maersk is confronting fresh uncertainty in the Strait of Hormuz as Iran seeks cryptocurrency toll payments during a temporary ceasefire, underlining how geopolitical and regulatory shifts can directly affect the company’s global...

As European markets navigate the complexities of Middle East tensions and energy market volatility, the pan-European STOXX Europe 600 Index has shown resilience, ending the week up 3.92% in local currency terms. This positive sentiment is supported by hopes for a shorter-lived conflict and is reflected in gains across major stock indexes like Germany's DAX and Italy's FTSE MIB. In this environment, identifying promising stocks involves looking for companies with strong fundamentals that can...

Why FLSmidth (CPSE:FLS) is in focus right now FLSmidth (CPSE:FLS) has just completed the sale of its former corporate headquarters in Valby, Denmark, a previously flagged transaction that brings in net cash proceeds and an accounting gain in Q1 2026. See our latest analysis for FLSmidth. The DKK504.5 share price has climbed 4.4% over the last day and 8.9% over 90 days. The 1 year total shareholder return of 86.6% points to strong longer term momentum, even after a recent 4.4% 1 month share...

Zealand Pharma (CPSE:ZEAL) recently announced a new research hub in Cambridge, Massachusetts. This facility will become its primary U.S. base and will focus on AI-driven drug discovery, advanced automation, and new therapeutic modalities. See our latest analysis for Zealand Pharma. The share price is DKK298.0 after a 1-day share price return of 1.02% and a 7-day share price return of 3.47%. However, the 30-day and year-to-date share price returns of -19.28% and -35.23% suggest recent momentum...

In late March 2026, Vestas Wind Systems announced a series of new wind turbine orders across Germany, France, the UK and the USA, alongside long-term service agreements and deliveries stretching from 2026 to 2028, and separately revealed plans for a more than €250 million nacelle and hub factory in Scotland targeting its V236-15.0 MW offshore turbines. Taken together, the fresh onshore order intake and the conditional Scottish offshore factory plan underline how Vestas is tying near-term...

Wondering whether Ørsted at DKK158.45 is starting to look like value, or still priced for high expectations? This article breaks down what the current share price may be implying. The stock has returned 9.2% over the last 7 days and 5.1% over the past month, yet over 1 year it is down 7.6% and over 5 years it is down 71.1%. This raises questions about how investors are reassessing both risk and potential. Recent attention on Ørsted has focused on its position in renewable energy and how...

Investors may be wondering whether Bavarian Nordic is attractively priced at its current level, or if the recent run has already incorporated most of the value. The stock last closed at kr197.25, with returns of 3.8% over 7 days, 2.4% over 30 days, 2.3% year to date, 30.7% over 1 year, 1.0% over 3 years, and a 31.8% decline over 5 years. Recent news coverage has focused on Bavarian Nordic's role in vaccines and biopharmaceuticals. This has kept attention on the company as investors reassess...

As European markets navigate heightened uncertainty due to geopolitical tensions and soaring energy costs, the pan-European STOXX Europe 600 Index has seen a notable decline of 3.79%. Amidst these challenges, investors may find opportunities in stocks that appear undervalued based on their intrinsic value, offering potential for growth when market conditions stabilize.

Lu AF28996 data puts H. Lundbeck (CPSE:HLUN B) pipeline in focus Fresh Phase 1b data for Lundbeck's Lu AF28996 in advanced Parkinson's disease, combined with new insights on multiple system atrophy, has pushed the drugmaker's research pipeline and long term neurology focus back into the spotlight. See our latest analysis for H. Lundbeck. At a share price of DKK37.64, Lundbeck has a 90 day share price return of a 12.47% decline and a 1 year total shareholder return of a 0.50% decline, so...

Lundbeck’s new clinical data on Lu AF28996 and the amlenetug program at the 2026 AD/PD conference has refocused attention on Genmab (CPSE:GMAB), given its collaboration role in developing amlenetug. See our latest analysis for Genmab. At a share price of DKK1,655.5, Genmab has a 1 day share price return of 1.13%, following a 30 day share price return decline of 10.68% and a 90 day share price return decline of 22.02%. The 1 year total shareholder return of 24.94% contrasts with weaker 3 and 5...

Bylaw changes and capital structure moves grab investor attention Embla Medical hf (CPSE:EMBLA) has drawn fresh interest after its 2026 Annual General Meeting approved share capital reductions, renewed board authorizations for future capital increases, and set out conditions for new share buyback and employee option programs. See our latest analysis for Embla Medical hf. Despite the AGM activity around buybacks and share capital, Embla Medical hf's share price has eased in recent months, with...

Bavarian Nordic A/S recently reported full-year 2025 results, with sales rising to DKK 6,243.96 million and net income reaching DKK 1,375.38 million, alongside higher earnings per share from continuing operations. A day earlier, the company expanded its partnership with Serum Institute of India to transfer chikungunya vaccine manufacturing and explore further co-development, potentially broadening access in low- and middle-income countries. Next, we’ll assess how the chikungunya tech...

Ørsted (CPSE:ORSTED) has proposed the election of three new board members at its annual general meeting scheduled for April 2026. The nominees are Karen Boesen, Karl Johnny Hersvik, and Samuel Leupold, each bringing experience in energy and renewables. Two current board members are not seeking re election, which would reshape the composition of Ørsted's board if the proposals are approved. For shareholders, these board changes come with Ørsted's share price at DKK144.0 and a mixed return...

Københavns Lufthavne (CPSE:KBHL) has wrapped up FY 2025 with Q4 revenue of DKK 1,368 million and basic EPS of DKK 32.95, while trailing twelve month figures sit at DKK 5.5 billion in revenue and EPS of DKK 158.00, reflecting earnings growth of 19.6% over the period. The company has seen quarterly revenue move from DKK 1,245 million and EPS of DKK 24.98 in Q4 2024 to DKK 1,368 million and EPS of DKK 32.95 in Q4 2025, with margins stepping up from 20% to 22%. This puts profitability at the...

Earlier this month, Zealand Pharma reported positive topline Phase 2 ZUPREME-1 results showing petrelintide achieved statistically significant, clinically meaningful weight loss with tolerability similar to placebo in people living with overweight and obesity. The data suggest petrelintide’s once-weekly amylin-based profile could offer a differentiated, potentially more tolerable alternative to existing peptide weight-loss therapies, reinforcing Zealand’s obesity franchise with Roche. We’ll...